Collegium Pharmaceutical(us:COLL)

    29.33

    -1.25%

    Updated on 2024-12-23

    Open:29.69
    Close:29.33
    High:30.19
    Low:28.97
    Pre Close:29.70
    Volume:212502.00
    Amount:6.22M
    Turnover:0.66%
    Shares:32.25M
    MarketCap:945.90M
    DateTotalTotal SharesTotal RatioNewIncreasedDecreased
    2024-06-3025539519065122.28%3492105
    2024-03-3123639765546121.59%487792
    2023-12-3120339199374123.00%295991
    2023-09-3019338694104117.04%177379
    2023-06-3021439303018113.21%1661110
    2023-03-3122039369429113.85%476685
    2022-12-3119036103213106.66%255483
    2022-09-3018935863109106.18%305769
    dateorgNametotalratiochangeShareschangeRatio
    2024-06-30Blackrock Inc.579338317.93%-72516-1.24%
    2024-06-30Pacer Advisors, Inc.340836910.55%82154131.76%
    2024-06-30Eventide Asset Management, Llc26346568.15%6150.02%
    2024-06-30Vanguard Group Inc23709427.34%402141.73%
    2024-06-30Rubric Capital Management Lp23335007.22%49947327.23%
    2024-06-30Invesco Ltd.17066105.28%749544.59%
    2024-06-30Principal Financial Group Inc16808605.20%1280038.24%
    2024-06-30Renaissance Technologies Llc15314984.74%1133007.99%
    2024-06-30State Street Corp13799534.27%608984.62%
    2024-06-30Fuller & Thaler Asset Management, Inc.11913733.69%22217422.92%

    About

    Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA.
    Address:100 Technology Center Drive,Suite 300

    Market Movers